Endoline
Sources: the KBO register on 20-11-2026; the National Bank, annual accounts to 30-06-2026 filed on 02-11-2026; the Belgian Official Gazette, latest deed of 21-11-2023.
Grounds
the facts the verdict rests on, each with its source- Endoline made a profit in every financial year since 2024. The profit of 2026, €134,807, is the highest so far.Annual accounts 2024 to 2026 page 2
- Equity stands at €240,271, or 76.5% of the balance sheet total of €314,283. In 2025, the solvency of 62.3% was higher than at 49% of the 21,373 companies filing micro accounts in human health (NACE 86).Annual accounts to 30-06-2026 page 2
- The last three annual accounts came in on time. The accounts to 30-06-2026 were filed 90 days before the end of the term.National Bank, filing of 02-11-2026 page 5
Representation
The signing rule is in the founding deed of 21-11-2023.
Articles of association, Belgian Official Gazette of 21-11-2023, deed 23429633
Ownership
The accounts in the micro format list no shareholders. founded Endoline by deed of 21-11-2023. There is one other shareholder.
Deed of 21-11-2023
Financial situation
Annual accounts 2024 to 2026, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 20247 months | 2025 | 2026 | Trend |
|---|---|---|---|---|
| Results | ||||
| Gross margin | €38,119 | €102,295 | €187,888 | |
| Operating result | €36,960 | €93,204 | €174,753 | |
| Net result | €29,179 | €73,285 | €134,807 | |
| Balance sheet at the closing date | ||||
| Equity | €32,179 | €105,465 | €240,271 | |
| Debts | €10,595 | €63,885 | €74,011 | |
| Debts due after more than one year | - | €35,366 | €25,704 | |
| Debts due within one year | €10,595 | €28,519 | €48,307 | |
| Cash | €6,325 | €66,941 | €189,768 | |
| Balance sheet total | €42,774 | €169,349 | €314,283 | |
| Ratios | ||||
| Solvency | 75.2% | 62.3% | 76.5% | |
| Liquidity | 4.04 | 3.95 | 5.59 | |
Source: Annual accounts to 30-06-2026, micro format, filed on 02-11-2026 (2026-00600474); Annual accounts to 30-06-2025, micro format, filed on 17-12-2025 (2025-00586480); Annual accounts 2024, filed on 15-11-2024 (2024-00600523).
The operating result of 2026 is 87% higher than in 2025.
Debts rose by €10,127 in 2026.
The annual accounts to 30-06-2026 state no amount of overdue tax or social security (RSZ) debts.
Endoline states no turnover; the micro format does not require it. The gross margin, what is left after purchases, rose from €102,295 to €187,888.
Board, signature and ownership
Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the founding deed of 21-11-2023.
Articles of association, Belgian Official Gazette of 21-11-2023, deed 23429633
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. founded Endoline by deed of 21-11-2023. holds all 100 shares.
Deed of 21-11-2023
Holdings
Endoline has 1 holding (own accounts to 30-06-2025).
| Country | Company | Equity | Result | |
|---|---|---|---|---|
| Belgium 1 | ||||
| BE | 11.07% | €20,949 | result -€6,491 | |
Source: List of holdings in its own accounts to 30-06-2025. Every holding stands with its own latest accounts.
Events and comparison
The last 24 months, newest first
Annual accounts 2026 filed, 90 days before the deadline.
NBB filingHighest result from 2024 to 2026. The operating result of €174,753 and the net result of €134,807 are both a record.
FinancialEquity above €200,000. With a profit in every financial year since 2024, equity grows to €240,271.
FinancialAnnual accounts 2025 filed, 45 days before the deadline.
NBB filingEquity above €100,000. With a profit in every financial year since 2024, equity grows to €105,465.
FinancialComparable companies, two years later
In July 2024, 39,332 companies had the same profile as Endoline has now: micro, 2 to 5 years old, solvency 30% or more and a profit of 5% of the balance sheet or more. Two years later 95.7% were still trading, 2.5% had stopped another way and 1.8% had gone bankrupt.
In 2025, the return on assets of Endoline, 43.3%, was higher than at 78% of the 21,223 companies filing micro accounts in human health (NACE 86).
Other findings
Peppol
Reachable for e-invoices since 11-12-2025, under 0208:1002392357.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 20-11-2026 | KBO 1002.392.357 |
| National Bank of Belgium | Annual accounts to 30-06-2026, micro format | 02-11-2026 | 2026-00600474 |
| National Bank of Belgium | Annual accounts to 30-06-2025, micro format | 17-12-2025 | 2025-00586480 |
| National Bank of Belgium | Annual accounts 2024 to 2024 | 15-11-2024 | 2024-00600523 |
| Belgian Official Gazette | Founding deed with the articles of association | 21-11-2023 | deed 23429633 |
| Peppol Directory | Registration for e-invoices | 11-12-2025 | 0208:1002392357 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 20-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 20-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.